share_log

EF Hutton Assumes Pasithea Therapeutics at Buy, Announces Price Target of $2

Benzinga ·  Jun 1, 2023 04:49

EF Hutton analyst Elemer Piros assumes Pasithea Therapeutics (NASDAQ:KTTA) with a Buy rating and announces Price Target of $2.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment